h-R3: Treatment of Head and Neck Cancer Treatment of Epithelial Tumors Anti-EGFR MAb

Abstract:

Epidermal growth factor receptor (EGFR) overexpression has been associated with alterations in cell cycle progression, increased invasive capacity, enhanced angiogenesis and decreased apoptosis of tumor cells. h-R3 is a genetically engineered humanized monoclonal antibody that recognizes an epitope located in the extracellular domain of human EGFR. The antibody blocks EGF binding to the receptor and inhibits its intrinsic tyrosine kinase activity. In preclinical experiments, h-R3 demonstrated remarkable anti-proliferative, proapoptotic and antiangiogenic effects. No significant signs of toxicity attributable to h-R3 were observed in animal studies. Phase I/II clinical studies in patients with advanced stage epithelial tumors or squamous cell carcinomas of the head and neck have demonstrated the efficacy and safety of single and multiple doses of the antibody in combination with radiotherapy.

Año de publicación:

2003

Keywords:

Fuente:

scopus